Odyssey Therapeutics, INC S-1 registration statements

Odyssey Therapeutics has filed a Rule 462(b) registration statement to increase its common stock offering by 2,599,000 shares.

Odyssey Therapeutics, Inc. has filed an amendment to its S-1 registration statement, detailing plans for an initial public offering of 13,240,000 shares of common stock with an estimated price range of $16.00 to $18.00 per share, aiming for a Nasdaq listing under the symbol ODTX.

Odyssey Therapeutics, a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases, has filed an S-1 registration statement with the SEC for an initial public offering.

Odyssey Therapeutics, a clinical-stage biopharmaceutical company, has filed an S-1 registration statement for an initial public offering, seeking to advance its pipeline of immunomodulatory therapies.